Cat# : VAC-0341
| Catalog# | Product Name | Availability | Size | Price | Qty |
|---|---|---|---|---|---|
| VAC-0341 | Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) | April 27, 2024 | 0.5ml | $1,998.00 |
|
| Add to Cart Online Order Request a Bulk Order | |||||
| Cat#: | VAC-0341 |
| Product Name: | Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) |
| Description: | Ad5-nCoV is a recombinant adenovirus type-5 vector (Ad5) vaccine currently being investigated for prophylaxis against SARS-CoV-2.1,2 It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute of Biotechnology, who in March 2020 announced the approval of a phase I clinical trial (ChiCTR2000030906)1 with an expected completion in December 2020. The study will evaluate antibody response in healthy patients between the ages of 18 and 60 who will receive one of three study doses, with follow-up taking place at weeks 2 and 4 and months 3 and 6 post-vaccination.2 |
| Biologic Classification: | Vaccines Recombinant |
For more information on how our products could help advance your project, please contact us.
ENTER YOUR EMAIL HERE TO SUBSCRIBE.
Copyright © 2024 Creative BioMart. All Rights Reserved.
